THOMAS G. WIGGANS - 25 Jan 2022 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role
Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Thomas G. Wiggans
Issuer symbol
N/A
Transactions as of
25 Jan 2022
Net transactions value
$0
Form type
4
Filing time
27 Jan 2022, 15:54:27 UTC
Previous filing
21 Jun 2021
Next filing
04 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Stock Option (right to buy) Award $0 +67,000 $0.000000 67,000 25 Jan 2022 Common Stock 67,000 $2.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/12 of the underlying shares monthly from January 1, 2022.